Exbio — Research products — Antibodies — CD and related antigens — Anti-Hu CD255 Purified

Anti-Hu CD255 Purified

Regulatory status

RUO

Antigen

CD255

Clone

CARL-1

Format

Purified

Reactivity

Human

Application

IHC, FC (QC tested)

Variant

0.1 mg

11-756-C100

In stock

143.00 USD

0.025 mg

11-756-C025

Delivery 1 week

71.50 USD

Variant

0.1 mg

11-756-C100

In stock

143.00 USD

0.025 mg

11-756-C025

Delivery 1 week

71.50 USD

Contact distributor

Product details

Description

Images

References

SDS download

Isotype

Mouse IgG3 kappa

Specificity

The mouse monoclonal antibody CARL-1 recognizes an extracellular epitope of CD255 / TWEAK, a type II transmembrane protein of the TNF superfamily able to induce apoptosis weakly in many cell types.

Application

IHC, FC (QC tested)

Application details

Flow cytometry: Recommended dilution: 1-4 μg/ml.

Reactivity

Human

Immunogen

human CD255-transfected 2PK-3 cells

Concentration

1 mg/ml

Preparation

Purified by protein-A affinity chromatography.

Formulation

Tris buffered saline (TBS), pH 8.0, 15 mM sodium azide

Storage and handling

Store at 2-8°C. Do not freeze.

The product is intended For Research Use Only. Diagnostic or therapeutic applications are strictly forbidden. Products shall not be used for resale or transfer to third parties either as a stand-alone product or as a manufacture component of another product without written consent of EXBIO Praha, a.s. EXBIO Praha, a.s. will not be held responsible for patent infringement or any other violations of intellectual property rights that may occur with the use of the products. Orders for all products are accepted subject to the Term and Conditions available at www.exbio.cz. EXBIO, EXBIO Logo, and all other trademarks are property of EXBIO Praha, a.s.

Other names

TNFSF12, APO3L, DR3LG, TWEAK, TNLG4A

Antigen description

CD255 / TWEAK (TNF-related weak inducer of apoptosis), a type II transmembrane protein expressed as membrane-bound and secreted form, can induce apoptosis in many tissues and cell lines through its receptor CD266 / TWEAK R. On the other hand, in endothelial cells this interaction can induce proliferation and promote angiogenesis including neovascularization of tumours. CD255 can act in a juxtacrine manner to initiate cellular responses, and induces secretion of pro-inflammatory cytokines. Besides CD266, CD255 may also bind to DR3.

Entrez Gene ID 8742

UniProt ID O43508

Separation of CD255 transfected l5178Y cells (red-filled) from CD255 nontransfected (WT) l5178Y cells (black-dashed) in flow cytometry analysis (surface staining) of l5178Y cell suspensions stained using anti-human CD255 (CARL-1) purified antibody (concentration in sample 3 μg/ml) GAM PE.

Product specific references:

Yoriki R, Akashi S, Sho M, Nomi T, Yamato I, Hotta K, Takayama T, Matsumoto S, Wakatsuki K, Migita K, Yagita H, Nakajima Y: Therapeutic potential of the TWEAK/Fn14 pathway in intractable gastrointestinal cancer. Exp Ther Med. 2011 Jan;2(1):103-108
PubMed

Nakayama M, Ishidoh K, Kojima Y, Harada N, Kominami E, Okumura K, Yagita H: Fibroblast growth factor-inducible 14 mediates multiple pathways of TWEAK-induced cell death. J Immunol. 2003 Jan 1;170(1):341-8.
PubMed

Hosokawa Y, Hosokawa I, Ozaki K, Nakae H, Matsuo T: Proinflammatory effects of tumour necrosis factor-like weak inducer of apoptosis (TWEAK) on human gingival fibroblasts. Clin Exp Immunol. 2006 Dec;146(3):540-9.
PubMed

Saitoh T, Nakayama M, Nakano H, Yagita H, Yamamoto N, Yamaoka S: TWEAK induces NF-kappaB2 p100 processing and long lasting NF-kappaB activation. J Biol Chem. 2003 Sep 19;278(38):36005-12.
PubMed

Brown SA, Ghosh A, Winkles JA: Full-length, membrane-anchored TWEAK can function as a juxtacrine signaling molecule and activate the NF-kappaB pathway. J Biol Chem. 2010 Jun 4;285(23):17432-41.
PubMed

Nakayama M, Kayagaki N, Yamaguchi N, Okumura K, Yagita H: Involvement of TWEAK in interferon gamma-stimulated monocyte cytotoxicity. J Exp Med. 2000 Nov 6;192(9):1373-80.
PubMed